Strattera Patent: Lilly Wins Infringement, But Inequitable Conduct Claims Continue

Lilly won a court ruling that seven generic manufacturers are infringing its Strattera (atomoxetine) patent. But the court declined to throw out claims by the generic firms that Lilly engaged in inequitable conduct in prosecuting the patent before the Patent and Trademark Office